PortalPublikationenConditioning regimens for allotransplants for diffuse large ...

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

Standard

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? / Bacher, Ulrike; Klyuchnikov, Evgeny; Le-Rademacher, Jennifer; Carreras, Jeanette; Armand, Philippe; Bishop, Michael R; Bredeson, Christopher N; Cairo, Mitchell S; Fenske, Timothy S; Freytes, Cesar O; Gale, Robert Peter; Gibson, John; Isola, Luis M; Inwards, David J; Laport, Ginna G; Lazarus, Hillard M; Maziarz, Richard T; Wiernik, Peter H; Schouten, Harry C; Slavin, Shimon; Smith, Sonali M; Vose, Julie M; Waller, Edmund K; Hari, Parameswaran N; Lymphoma, Working Committee Of The CIBMTR.

in: BLOOD, Jahrgang 120, Nr. 20, 20, 15.11.2012, S. 4256-4262.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Bacher, U, Klyuchnikov, E, Le-Rademacher, J, Carreras, J, Armand, P, Bishop, MR, Bredeson, CN, Cairo, MS, Fenske, TS, Freytes, CO, Gale, RP, Gibson, J, Isola, LM, Inwards, DJ, Laport, GG, Lazarus, HM, Maziarz, RT, Wiernik, PH, Schouten, HC, Slavin, S, Smith, SM, Vose, JM, Waller, EK, Hari, PN & Lymphoma, WCOTCIBMTR 2012, 'Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?', BLOOD, Jg. 120, Nr. 20, 20, S. 4256-4262. https://doi.org/10.1182/blood-2012-06-436725

APA

Bacher, U., Klyuchnikov, E., Le-Rademacher, J., Carreras, J., Armand, P., Bishop, M. R., Bredeson, C. N., Cairo, M. S., Fenske, T. S., Freytes, C. O., Gale, R. P., Gibson, J., Isola, L. M., Inwards, D. J., Laport, G. G., Lazarus, H. M., Maziarz, R. T., Wiernik, P. H., Schouten, H. C., ... Lymphoma, W. C. O. T. CIBMTR. (2012). Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? BLOOD, 120(20), 4256-4262. [20]. https://doi.org/10.1182/blood-2012-06-436725

Vancouver

Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? BLOOD. 2012 Nov 15;120(20):4256-4262. 20. https://doi.org/10.1182/blood-2012-06-436725

Bibtex

@article{c54cf7365a354e87ac586a87e3019e55,
title = "Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?",
abstract = "The best conditioning regimen before allogeneic transplantation for high-risk diffuse large B-cell lymphoma (DLBCL) remains to be clarified. We analyzed data from 396 recipients of allotransplants for DLBCL receiving myeloablative (MAC; n = 165), reduced intensity (RIC; n = 143), or nonmyeloablative conditioning (NMAC; n = 88) regimens. Acute and chronic GVHD rates were similar across the groups. Five-year nonrelapse mortality (NRM) was higher in MAC than RIC and NMAC (56% vs 47% vs 36%; P = .007). Five-year relapse/progression was lower in MAC than in RIC/NMAC (26% vs 38% vs 40%; P = .031). Five-year progression-free survival (15%-25%) and overall survival (18%-26%) did not differ significantly between the cohorts. In multivariate analysis, NMAC and more recent transplant year were associated with lower NRM, whereas a lower Karnofsky performance score (< 90), prior relapse resistant to therapy, and use of unrelated donors were associated with higher NRM. NMAC transplants, no prior use of rituximab, and prior relapse resistant to therapy were associated with a greater risk of relapse/progression. In conclusion, allotransplantation with RIC or NMAC induces long-term progression-free survival in selected DLBCL patients with a lower risk of NRM but with higher risk of lymphoma progression or relapse.",
keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Adolescent, Young Adult, Treatment Outcome, Combined Modality Therapy, Disease-Free Survival, Disease Progression, Chronic Disease, Retrospective Studies, Recurrence, Acute Disease, Kaplan-Meier Estimate, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Transplantation Conditioning/*methods, Graft vs Host Disease/epidemiology/etiology/prevention & control, Hematopoietic Stem Cell Transplantation/adverse effects, Histocompatibility, Lymphoma, Large B-Cell, Diffuse/drug therapy/*surgery, Myeloablative Agonists/*administration & dosage/adverse effects, Transplantation, Homologous/adverse effects, *Whole-Body Irradiation/adverse effects, Adult, Humans, Male, Aged, Female, Middle Aged, Adolescent, Young Adult, Treatment Outcome, Combined Modality Therapy, Disease-Free Survival, Disease Progression, Chronic Disease, Retrospective Studies, Recurrence, Acute Disease, Kaplan-Meier Estimate, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Transplantation Conditioning/*methods, Graft vs Host Disease/epidemiology/etiology/prevention & control, Hematopoietic Stem Cell Transplantation/adverse effects, Histocompatibility, Lymphoma, Large B-Cell, Diffuse/drug therapy/*surgery, Myeloablative Agonists/*administration & dosage/adverse effects, Transplantation, Homologous/adverse effects, *Whole-Body Irradiation/adverse effects",
author = "Ulrike Bacher and Evgeny Klyuchnikov and Jennifer Le-Rademacher and Jeanette Carreras and Philippe Armand and Bishop, {Michael R} and Bredeson, {Christopher N} and Cairo, {Mitchell S} and Fenske, {Timothy S} and Freytes, {Cesar O} and Gale, {Robert Peter} and John Gibson and Isola, {Luis M} and Inwards, {David J} and Laport, {Ginna G} and Lazarus, {Hillard M} and Maziarz, {Richard T} and Wiernik, {Peter H} and Schouten, {Harry C} and Shimon Slavin and Smith, {Sonali M} and Vose, {Julie M} and Waller, {Edmund K} and Hari, {Parameswaran N} and Lymphoma, {Working Committee Of The CIBMTR}",
year = "2012",
month = nov,
day = "15",
doi = "10.1182/blood-2012-06-436725",
language = "English",
volume = "120",
pages = "4256--4262",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "20",

}

RIS

TY - JOUR

T1 - Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

AU - Bacher, Ulrike

AU - Klyuchnikov, Evgeny

AU - Le-Rademacher, Jennifer

AU - Carreras, Jeanette

AU - Armand, Philippe

AU - Bishop, Michael R

AU - Bredeson, Christopher N

AU - Cairo, Mitchell S

AU - Fenske, Timothy S

AU - Freytes, Cesar O

AU - Gale, Robert Peter

AU - Gibson, John

AU - Isola, Luis M

AU - Inwards, David J

AU - Laport, Ginna G

AU - Lazarus, Hillard M

AU - Maziarz, Richard T

AU - Wiernik, Peter H

AU - Schouten, Harry C

AU - Slavin, Shimon

AU - Smith, Sonali M

AU - Vose, Julie M

AU - Waller, Edmund K

AU - Hari, Parameswaran N

AU - Lymphoma, Working Committee Of The CIBMTR

PY - 2012/11/15

Y1 - 2012/11/15

N2 - The best conditioning regimen before allogeneic transplantation for high-risk diffuse large B-cell lymphoma (DLBCL) remains to be clarified. We analyzed data from 396 recipients of allotransplants for DLBCL receiving myeloablative (MAC; n = 165), reduced intensity (RIC; n = 143), or nonmyeloablative conditioning (NMAC; n = 88) regimens. Acute and chronic GVHD rates were similar across the groups. Five-year nonrelapse mortality (NRM) was higher in MAC than RIC and NMAC (56% vs 47% vs 36%; P = .007). Five-year relapse/progression was lower in MAC than in RIC/NMAC (26% vs 38% vs 40%; P = .031). Five-year progression-free survival (15%-25%) and overall survival (18%-26%) did not differ significantly between the cohorts. In multivariate analysis, NMAC and more recent transplant year were associated with lower NRM, whereas a lower Karnofsky performance score (< 90), prior relapse resistant to therapy, and use of unrelated donors were associated with higher NRM. NMAC transplants, no prior use of rituximab, and prior relapse resistant to therapy were associated with a greater risk of relapse/progression. In conclusion, allotransplantation with RIC or NMAC induces long-term progression-free survival in selected DLBCL patients with a lower risk of NRM but with higher risk of lymphoma progression or relapse.

AB - The best conditioning regimen before allogeneic transplantation for high-risk diffuse large B-cell lymphoma (DLBCL) remains to be clarified. We analyzed data from 396 recipients of allotransplants for DLBCL receiving myeloablative (MAC; n = 165), reduced intensity (RIC; n = 143), or nonmyeloablative conditioning (NMAC; n = 88) regimens. Acute and chronic GVHD rates were similar across the groups. Five-year nonrelapse mortality (NRM) was higher in MAC than RIC and NMAC (56% vs 47% vs 36%; P = .007). Five-year relapse/progression was lower in MAC than in RIC/NMAC (26% vs 38% vs 40%; P = .031). Five-year progression-free survival (15%-25%) and overall survival (18%-26%) did not differ significantly between the cohorts. In multivariate analysis, NMAC and more recent transplant year were associated with lower NRM, whereas a lower Karnofsky performance score (< 90), prior relapse resistant to therapy, and use of unrelated donors were associated with higher NRM. NMAC transplants, no prior use of rituximab, and prior relapse resistant to therapy were associated with a greater risk of relapse/progression. In conclusion, allotransplantation with RIC or NMAC induces long-term progression-free survival in selected DLBCL patients with a lower risk of NRM but with higher risk of lymphoma progression or relapse.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Adolescent

KW - Young Adult

KW - Treatment Outcome

KW - Combined Modality Therapy

KW - Disease-Free Survival

KW - Disease Progression

KW - Chronic Disease

KW - Retrospective Studies

KW - Recurrence

KW - Acute Disease

KW - Kaplan-Meier Estimate

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Transplantation Conditioning/methods

KW - Graft vs Host Disease/epidemiology/etiology/prevention & control

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Histocompatibility

KW - Lymphoma, Large B-Cell, Diffuse/drug therapy/surgery

KW - Myeloablative Agonists/administration & dosage/adverse effects

KW - Transplantation, Homologous/adverse effects

KW - Whole-Body Irradiation/adverse effects

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Adolescent

KW - Young Adult

KW - Treatment Outcome

KW - Combined Modality Therapy

KW - Disease-Free Survival

KW - Disease Progression

KW - Chronic Disease

KW - Retrospective Studies

KW - Recurrence

KW - Acute Disease

KW - Kaplan-Meier Estimate

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Transplantation Conditioning/methods

KW - Graft vs Host Disease/epidemiology/etiology/prevention & control

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Histocompatibility

KW - Lymphoma, Large B-Cell, Diffuse/drug therapy/surgery

KW - Myeloablative Agonists/administration & dosage/adverse effects

KW - Transplantation, Homologous/adverse effects

KW - Whole-Body Irradiation/adverse effects

U2 - 10.1182/blood-2012-06-436725

DO - 10.1182/blood-2012-06-436725

M3 - SCORING: Journal article

C2 - 23007405

VL - 120

SP - 4256

EP - 4262

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 20

M1 - 20

ER -